ketoconazole has been researched along with Neutropenia in 33 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study evaluated the activity of ketoconazole in neutropenic dogs with systemic candidiasis." | 7.67 | Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. ( Epstein, RB; Gawith, KE; Keppen, M; Weber, MJ, 1985) |
| " There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients." | 5.28 | Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. ( Boogaerts, MA; De Beule, K; Demuynck, H; Verbist, L; Verhoef, GE; Zachee, P, 1989) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 5.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| " In a neutropenic mouse model, itraconazole appeared to be as effective as amphotericin B against Candida albicans, and was more effective than amphotericin B in treating an Aspergillus infection in a patient with chronic granulomatous disease." | 5.07 | Itraconazole in neutropenic patients. ( van't Wout, JW, 1992) |
| "We compared the efficacies of the new triazole antifungal drugs fluconazole and itraconazole with that of amphotericin B in vitro and in an animal model of systemic candidiasis in normal and neutropenic mice." | 3.67 | Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. ( Mattie, H; van Furth, R; Van t Wout, JW, 1989) |
| "The present study evaluated the activity of ketoconazole in neutropenic dogs with systemic candidiasis." | 3.67 | Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. ( Epstein, RB; Gawith, KE; Keppen, M; Weber, MJ, 1985) |
| "Etoposide is a widely used cytotoxic drug that is commercially available in both intravenous and oral formulations." | 2.73 | Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. ( Desai, AA; Fleming, GF; House, L; Innocenti, F; Kobayashi, K; Ramirez, J; Ratain, MJ; Schilsky, RL; Shepard, D; Vogelzang, NJ; Yong, WP, 2007) |
| "Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
| "Amphotericin B may have been more effective than ketoconazole for the treatment of pneumonia." | 2.66 | Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. ( Bodey, GP; Elting, L; Fainstein, V; Keating, M; Maksymiuk, A; McCredie, KB, 1987) |
| "Ketoconazole was administered in a 200 mg dose twice daily." | 2.66 | A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. ( Malcom, LG; Vogler, WR; Winton, EF, 1987) |
| "Ketoconazole was better tolerated and more effective than nystatin in reducing colonization due to Candida species but was also associated with significantly increased rates of colonization with T." | 2.66 | Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. ( Klosterman, A; Meyers, JD; Shepp, DH; Siegel, MS, 1985) |
| "Ketoconazole or miconazole was randomly administered to 42 and 46 neutropenic patients respectively." | 2.65 | Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. ( Cruciani, M; Klastersky, J; Meunier-Carpentier, F, 1983) |
| "Ketoconazole was better tolerated than nystatin and neither drug caused toxic effects." | 2.65 | Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. ( Bergman, AG; Jones, PG; Kauffman, CA; Liepman, MK; McAuliffe, LS, 1984) |
| "Patients with cancer complicated by neutropenia." | 2.40 | Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. ( Gøtzsche, PC; Johansen, HK, 1997) |
| "Amphotericin B is the treatment of choice for acute and chronic hematogenously disseminated candidiasis." | 1.29 | Severe candidal infections in neutropenic patients. ( Edwards, JE; Filler, SG; Swerdloff, JN, 1993) |
| " There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients." | 1.28 | Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. ( Boogaerts, MA; De Beule, K; Demuynck, H; Verbist, L; Verhoef, GE; Zachee, P, 1989) |
| "Invasive fungal infections are becoming increasingly frequent among immunocompromised patients and especially among cancer patients." | 1.27 | Treatment of mycoses in cancer patients. ( Meunier-Carpentier, F, 1983) |
| "Candidiasis was established by intravenously administering Candida albicans or Candida tropicalis (1-2 x 10(5) colony-forming units) and resulted in hepatic and splenic lesions that mimicked those associated with hepatosplenic candidiasis in humans." | 1.27 | Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. ( Bacher, J; O'Leary, T; Pizzo, PA; Thaler, M, 1988) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 1.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (57.58) | 18.7374 |
| 1990's | 10 (30.30) | 18.2507 |
| 2000's | 4 (12.12) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minenko, SV | 1 |
| Zhukov, NV | 1 |
| Chimishkian, KL | 1 |
| Sokolova, EN | 1 |
| Ptushkin, VV | 1 |
| Yong, WP | 2 |
| Desai, AA | 1 |
| Innocenti, F | 1 |
| Ramirez, J | 1 |
| Shepard, D | 1 |
| Kobayashi, K | 1 |
| House, L | 1 |
| Fleming, GF | 1 |
| Vogelzang, NJ | 1 |
| Schilsky, RL | 1 |
| Ratain, MJ | 1 |
| Wang, LZ | 1 |
| Tham, LS | 1 |
| Wong, CI | 1 |
| Lee, SC | 1 |
| Soo, R | 1 |
| Sukri, N | 1 |
| Lee, HS | 1 |
| Goh, BC | 1 |
| Maksymiuk, AW | 1 |
| Thongprasert, S | 1 |
| Hopfer, R | 1 |
| Luna, M | 1 |
| Fainstein, V | 2 |
| Bodey, GP | 2 |
| Hann, IM | 1 |
| Prentice, HG | 2 |
| Corringham, R | 1 |
| Blacklock, HA | 1 |
| Keaney, M | 1 |
| Shannon, M | 1 |
| Noone, P | 1 |
| Gascoigne, E | 1 |
| Fox, J | 1 |
| Boesen, E | 1 |
| Szawatkowski, M | 1 |
| Hoffbrand, AV | 1 |
| Donnelly, JP | 1 |
| Starke, ID | 1 |
| Galton, DA | 1 |
| Catovsky, D | 1 |
| Goldman, JM | 1 |
| Darrell, JH | 1 |
| Meunier-Carpentier, F | 3 |
| Cruciani, M | 1 |
| Klastersky, J | 1 |
| Jones, PG | 1 |
| Kauffman, CA | 1 |
| McAuliffe, LS | 1 |
| Liepman, MK | 1 |
| Bergman, AG | 1 |
| Swerdloff, JN | 1 |
| Filler, SG | 1 |
| Edwards, JE | 1 |
| Moore, L | 1 |
| Ellis, DH | 1 |
| Suppiah, R | 1 |
| Byard, RW | 1 |
| Toogood, IR | 1 |
| Gøtzsche, PC | 1 |
| Johansen, HK | 1 |
| Burgaleta, C | 1 |
| Paterson, PJ | 1 |
| McWhinney, PH | 1 |
| Potter, M | 1 |
| Kibbler, CC | 1 |
| van't Wout, JW | 2 |
| Persat, F | 1 |
| Marzullo, C | 1 |
| Guyotat, D | 1 |
| Rochet, MJ | 1 |
| Piens, MA | 1 |
| Hendriks, WD | 2 |
| Sizoo, W | 2 |
| Palmblad, J | 1 |
| Lönnqvist, B | 1 |
| Carlsson, B | 1 |
| Grimfors, G | 1 |
| Järnmark, M | 1 |
| Lerner, R | 1 |
| Ljungman, P | 1 |
| Nyström-Rosander, C | 1 |
| Petrini, B | 1 |
| Oberg, G | 1 |
| Thunnissen, PL | 1 |
| Novakova, I | 1 |
| Verhagen, CA | 1 |
| Fibbe, WE | 1 |
| de Pauw, BE | 1 |
| van der Meer, JW | 1 |
| Van t Wout, JW | 1 |
| Mattie, H | 1 |
| van Furth, R | 1 |
| Boogaerts, MA | 1 |
| Verhoef, GE | 1 |
| Zachee, P | 1 |
| Demuynck, H | 1 |
| Verbist, L | 1 |
| De Beule, K | 2 |
| Ninane, J | 1 |
| Sluysmans, T | 1 |
| Vermylen, C | 1 |
| Woestenborghs, R | 1 |
| Cauwenbergh, G | 1 |
| Cornu, G | 1 |
| Koletzko, B | 1 |
| Wendel, U | 1 |
| Bremer, HJ | 1 |
| Thaler, M | 1 |
| Bacher, J | 1 |
| O'Leary, T | 1 |
| Pizzo, PA | 1 |
| von Paleske, A | 1 |
| Müllerleile, U | 1 |
| Gressler, V | 1 |
| Garbrecht, M | 1 |
| Hossfeld, DK | 1 |
| Hughes, CE | 1 |
| Peterson, LR | 1 |
| Beggs, WH | 1 |
| Gerding, DN | 1 |
| Elting, L | 1 |
| Maksymiuk, A | 1 |
| Keating, M | 1 |
| McCredie, KB | 1 |
| Vogler, WR | 1 |
| Malcom, LG | 1 |
| Winton, EF | 1 |
| Weber, MJ | 1 |
| Keppen, M | 1 |
| Gawith, KE | 1 |
| Epstein, RB | 1 |
| Shepp, DH | 1 |
| Klosterman, A | 1 |
| Siegel, MS | 1 |
| Meyers, JD | 1 |
| Schaffner, A | 1 |
| Frick, PG | 1 |
2 reviews available for ketoconazole and Neutropenia
| Article | Year |
|---|---|
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Miconazole; Myco | 1997 |
[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Candidia | 1995 |
14 trials available for ketoconazole and Neutropenia
| Article | Year |
|---|---|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents, Phyt | 2007 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.
Topics: Amphotericin B; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Imidazoles; Immunosuppr | 1982 |
Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia.
Topics: Adolescent; Adult; Amphotericin B; Antineoplastic Agents; Candidiasis, Oral; Candidiasis, Vulvovagin | 1984 |
Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients.
Topics: Agranulocytosis; Antifungal Agents; Candidiasis; Drug Combinations; Female; Humans; Imidazoles; Keto | 1983 |
Prophylaxis of fungal infections in neutropenic cancer patients.
Topics: Agranulocytosis; Amphotericin B; Aspergillosis; Candidiasis; Clinical Trials as Topic; Humans; Ketoc | 1983 |
Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients.
Topics: Adult; Agranulocytosis; Female; Humans; Ketoconazole; Male; Middle Aged; Mycoses; Neutropenia; Nysta | 1984 |
Itraconazole in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Humans; Itraconazole; Ketoconazole; M | 1992 |
Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candidiasis; Humans; Incidence; Ketocona | 1992 |
The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B.
Topics: Amphotericin B; Aspergillosis; Aspergillus fumigatus; Candidiasis; Drug Therapy, Combination; Female | 1991 |
Itraconazole versus ketoconazole for the prophylaxis of fungal infection in neutropenic children: results of two consecutive nonrandomized studies.
Topics: Adolescent; Agranulocytosis; Antifungal Agents; Child; Child, Preschool; Clinical Trials as Topic; F | 1989 |
Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Female; Humans; Ketoconazole; Male; Middle Aged; Mycoses; N | 1987 |
A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Candidiasis, Oral; Female; Humans; Immune T | 1987 |
Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment.
Topics: Agranulocytosis; Candida albicans; Candidiasis; Clinical Trials as Topic; Environment, Controlled; H | 1985 |
17 other studies available for ketoconazole and Neutropenia
| Article | Year |
|---|---|
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema | 2004 |
Systemic candidiasis in cancer patients.
Topics: Acute Disease; Amphotericin B; Bacterial Infections; Bacteriological Techniques; Candida; Candidiasi | 1984 |
Treatment of mycoses in cancer patients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Candidiasis, Oral; Drug Therapy, Comb | 1983 |
Severe candidal infections in neutropenic patients.
Topics: Amphotericin B; Candidiasis; Fluconazole; Humans; Itraconazole; Ketoconazole; Neutropenia | 1993 |
Complete eradication of Aspergillus fumigatus from the lung in an immunocompromised patient by oral itraconazole.
Topics: Administration, Oral; Adolescent; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R | 2001 |
Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Th | 1992 |
Possible failure of itraconazole in preventing fungal infection in a neutropenic leukaemia patient.
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Aspergillus niger; Humans; Itraconazole; Ke | 1992 |
Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Female; Humans; Itraconazole; Ketoconazole; Male; Middle | 1991 |
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Fluconaz | 1989 |
Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.
Topics: Adult; Aged; Agranulocytosis; Antifungal Agents; Female; Humans; Itraconazole; Ketoconazole; Male; M | 1989 |
Lithium for treatment of neutropenia in glycogen storage disease type Ib.
Topics: Agranulocytosis; Chlorides; Drug Combinations; Drug Therapy, Combination; Female; Glycogen Storage D | 1986 |
Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candidiasis; Cytarabine; Drug Evaluatio | 1988 |
Incidence and treatment of fungal infections in neutropenic patients.
Topics: Agranulocytosis; Amphotericin B; Female; Humans; Ketoconazole; Leukemia, Lymphoid; Leukemia, Myeloid | 1987 |
Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits.
Topics: Animals; Candida; Candida albicans; Candidiasis; Drug Synergism; Drug Therapy, Combination; Flucytos | 1986 |
Treatment of systemic candidiasis in neutropenic dogs with ketoconazole.
Topics: Agranulocytosis; Animals; Bone Marrow; Bone Marrow Transplantation; Candida albicans; Candidiasis; D | 1985 |
The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.
Topics: Amphotericin B; Animals; Aspergillosis; Disease Models, Animal; Female; Humans; In Vitro Techniques; | 1985 |